[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"oat\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:oat":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100654447","phase-1-characterization-of-cb1-receptors-using-11-comar-in-opioid-use-disorder-100654447",false,"NCT07800520","Characterization of CB1 Receptors Using [11-C]OMAR in Opioid Use Disorder","Inclusion Criteria:\n\nAll\n\n* Normal screening bloodwork.\n* Adequate arterial access for placement of an arterial line and blood sampling per study protocol.\n\nOUD Participants:\n\n* Diagnosis of opioid use disorder (OUD) according to DSM-5 criteria.\n* Actively seeking treatment for OUD.\n* Willingness to initiate opioid agonist therapy (OAT) with buprenorphine.\n\nHealthy Controls:\n\n* Good general physical health.\n* No current or past diagnosis of any psychiatric or substance use disorders.\n\nExclusion Criteria:\n\nAll\n\n* Any current major medical condition that, in the opinion of the Principal Investigator, poses a risk for PET procedures.\n* Prior participation in research studies within the past year that would result in cumulative radiation exposure exceeding annual limits.\n* Presence of ferromagnetic metal in the body, pacemaker, or other contraindications to MRI.\n* Positive pregnancy test or current lactation.\n* History of neurological conditions, including stroke or seizure disorders.\n* Hematocrit values lower than 30\n\nOUD Participants\n\n* Current or past diagnosis of a serious psychiatric disorder.\n* Current diagnosis of any substance use disorder other than nicotine or opioids.\n* Use of any substances within the past 30 days.\n* Current use of SSRIs or benzodiazepines or use within the past 30 days.\n* Previous enrollment in the main study.\n\nHealthy Controls:\n\n* Current or past diagnosis of any psychiatric disorder.\n* Current diagnosis of any substance use disorder (excluding nicotine).\n* Use of any substances within the past 30 days.",true,"ALL","25 Years","65 Years",{"count":20,"type":21},110,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","The goals of this sub-study is to assess CB1R availability in early abstinent individuals with OUD (following opioid agonist therapy - OAT stabilization) and in matched healthy controls.",[27,28],"Opioid Use Disorder","OAT","RECRUITING","2026-10-01",{"date":32,"type":33},"2026-10-02","ACTUAL",{"date":30,"type":33},{"date":36,"type":21},"2030-08",{"name":38,"class":39},"Yale University","OTHER"]